Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study

World Journal of Gastroenterology

Volumn 15, Issue 47, 2009, Pages 5946-5952

  Gramenzi, Annagiulia ^a   Cursaro, Carmela ^a   Margotti, Marzia ^a   Balsano, Clara ^b,c   Spaziani, Alessandra ^b   Anticoli, Simona ^b   Loggi, Elisabetta ^a   Salerno, Maddalena ^d   Galli, Silvia ^e   Furlini, Giuliano ^e   Bernardi, Mauro ^a   Andreone, Pietro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d Hospital of Paola   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic hepatitis C; Clinical pharmacology; Liver; Non steroidal antiinflammatory drugs; Viral hepatitis

Indexed keywords

ADENOSINE PHOSPHATE; ALANINE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; KETOPROFEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; STAT1 PROTEIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INSOMNIA; MALE; MENTAL DISEASE; MYALGIA; NEUTROPENIA; PATIENT COMPLIANCE; PNEUMONIA; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS GENE; VIRUS LOAD;

EID: 75449089723     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.5946     Document Type: Article

References (27)

1. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789
2. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998; 352: 1426-1432
3. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499
4. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36: S3-S20
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
7. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
8. Hannigan GE, Williams BR. Signal transduction by interferonalpha through arachidonic acid metabolism. Science 1991; 251: 204-207
9. Tsuboi I, Tanaka H, Nakao M, Shichijo S, Itoh K. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine 1995; 7: 372-379
10. Baskin G. Interferon signalling through arachidonic aciddependent pathways: a clue to adjuvant therapy for chronic viral hepatitis? Hepatology 1991; 14: 392-394
11. Andreone P, Cursaro C, Gasbarrini G. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can nonsteroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993; 19: 228-231
12. Andreone P, Cursaro C, Gramenzi A, Buzzi A, Miniero R, Sprovieri G, Gasbarrini G. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis. J Hepatol 1994; 21: 984-988
13. Giambartolomei S, Artini M, Almerighi C, Moavero SM, Levrero M, Balsano C. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology 1999; 30: 510-516
14. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004; 24: 439-454
15. Trujillo-Murillo K, Rincón-Sánchez AR, Martínez-Rodríguez H, Bosques-Padilla F, Ramos-Jiménez J, Barrera-Saldaña HA, Rojkind M, Rivas-Estilla AM. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008; 47: 1462-1472
16. Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, Bacq Y, Combis JM, Causse X, Tran A, Oberti F, Minello A, Bresson-Hadni S, Bailly F, Raabe JJ, Leroy V, Hamici L, Hicham T, Girardin MF. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998; 27: 862-867
17. Andreone P, Cursaro C, Gramenzi A, Fiorino S, Di Giammarino L, Miniero R, D'Errico A, Grigioni WF, Gasbarrini G, Bernardi M. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study. Ital J Gastroenterol Hepatol 1999; 31: 688-694
18. Fabris P, Tositti G, Negro F, Marranconi F, Infantolino D, Rassu M, De Lalla F. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Aliment Pharmacol Ther 1999; 13: 1329-1334
19. Muñoz AE, Levi D, Podestá A, Gorín JM, González J, Bartellini MA, Munne MS, Cabanne A, Flichman D, Terg R. Interferonalpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. Gut 2000; 46: 427-431
20. Andreone P, Gramenzi A, Cursaro C, Biselli M, Lorenzini S, Loggi E, Felline F, Fiorino S, Di Giammarino L, Porzio F, Galli S, Bernardi M. Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial. J Viral Hepat 2003; 10: 306-309
21. Hadziyannis SJ. Combination of interferon alpha therapy with non-steroidal anti-inflammatory drugs in chronic hepatitis C. Gut 2000; 46: 306-307
22. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
23. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46: 16-21
24. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-1358
25. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, Brasier AR. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003; 77: 5933-5947
26. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47
27. Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008; 15: 2-11